H.C. Wainwright reiterates Mineralys stock rating on FDA acceptance By Investing.com

FDA accepted Mineralys' NDA for lorundrostat with a PDUFA date of December 22, 2026, marking material regulatory progress. Lorundrostat showed a clinically meaningful blood-pressure reduction of ~11.1 mmHg but missed the Phase 2 Explore-OSA primary endpoint for sleep apnea at 4 weeks. H.C. Wainwright reiterated a Buy with a $56 target and Stifel raised its target to $52 (from $45); the stock trades around $27.24 with analyst targets in the $42–$56 range.

Analysis

The market is pricing this story as an idiosyncratic regulatory/commercial binary inside a broader bullish biotech tape; the non-obvious leverage is that a favorable regulatory outcome doesn’t just lift share price — it materially re-frames payer negotiations and physician adoption curves because third-party guideline recognition (and high-impact journal visibility) accelerates formulary inclusion and specialty-prescriber uptake. That means upside will be concentrated in the 12–36 month commercial ramp rather than a one-off post-approval pop, creating multi-stage value realization (approval → formulary access → primary-care penetration).

Missed or noisy signal(s) in ancillary indications expose a different risk: the company now must defend a focused label and demonstrate clear cost-effectiveness versus entrenched cheap alternatives and non-pharmacologic options (e.g., device-based interventions). Payers are likely to demand narrow coverage or step-therapy initially, which caps near-term realized revenue even with approval — so valuation should reflect a long, top-line-weighted rollout rather than instant peak sales.

On the supply/operational side, small-cap developers frequently underprice CMC and manufacturing scale risks; the real second-order hit would be a constrained launch due to API/CMO bottlenecks or delayed REMS-type distribution, which can turn clinical/regulatory wins into commercial misses. Finally, the best hedge is isolating the binary regulatory risk from the secular hypertension market opportunity — use relative-value structures and calendar spreads to harvest the asymmetric optionality without full equity exposure.

Key Decisions for Investors

• Buy a cost-limited call spread to own upside into the regulatory decision: establish MLYS Jan 2027 30/60 call spread (buy 30c / sell 60c) sized to 2–3% portfolio equity risk. Rationale: caps premium paid while keeping ~3–4x upside if approval + favorable label; stop and trim on >40% intraday pop post-decision to lock gains.
• Sell short-dated, 20% OTM puts to accumulate stock at a discount if comfortable owning the name: sell MLYS 6-month 20% OTM puts (cash-secured). Reward: collect premium and lower basis; risk: assignment and full equity downside if adverse regulatory outcome — size position to max 3% portfolio on assignment.
• Pair trade to isolate idiosyncratic regulatory risk: long MLYS equity (small-sized) paired with short equal dollar exposure to XBI (or a broader small-cap biotech ETF) for 6–12 months. This reduces market beta and leaves the thesis driven by company-specific regulatory/commercial readouts.
• For long-term holders who want exposure but less binary volatility: buy LEAPS (Jan 2028) and sell near-term calls (3–6 months) to finance the premium. Aim to retain optional upside from 2027–2028 commercialization while monetizing near-term implied volatility decay.